Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol - Swenson, Colin E; Hunt, William R; Manfredi, Candela; Beltran, Diana J; Hong, Jeong S; Davis, Brian R; Suzuki, Shingo; Barillá, Cristina; Rab, Andras; Chico, Cynthia; Dangerfield, Joy; Streby, Ashleigh; et al. (PloS one, 2025)
Keywords: Adult; Air flow; Aminophenols - administration & dosage; Aminophenols - therapeutic use; Benzodioxoles - therapeutic use; Biopsy; Bronchiectasis; Bronchiectasis - drug therapy; Bronchiectasis - genetics; Cell differentiation; Chloride; Chloride Channel Agonists - therapeutic use; Chloride conductance; Chlorides; Consent; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator - genetics; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism; Diagnosis; Differentiation (biology); Drug Combinations; Female; Health services; Humans; In vitro methods and tests; Indoles - administration & dosage; Indoles - therapeutic use; Infections; Inflammation; Ion transport; Laboratories; Lung diseases; Male; Middle Aged; Monolayers; Mutation; Pathogenesis; Patients; Pyrazoles - therapeutic use; Pyridines - therapeutic use; Pyrrolidines - therapeutic use; Quality of life; Quinolines; Quinolones - therapeutic use; Respiratory tract infection; Sputum; Sweat; Toxins; Treatment Outcome; United States--US